Market Overview 2022-2027

IMARC Group has recently released a new research study “Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What are the growth prospects of the Ovarian Cancer Industry?

The global ovarian cancer market size reached US$ 1.68 Billionin 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.34 Billionby 2027, exhibiting a growth rate (CAGR) of 11.40%during 2022-2027.

Impact of COVID-19:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request For Sample Report https://www.imarcgroup.com/ovarian-cancer-market/requestsample

What is a Ovarian Cancer Market ?

Ovarian cancer represents a malignant tumor wherein irregular cells in the ovary begin to develop and multiply uncontrollably from the outer tissue lining or fallopian tubes, owing to mutagenic changes in the deoxyribonucleic acid (DNA). It can be treated through various diagnoses and drugs, such as antineoplastics, antirheumatics, mitotic, PARP, and VEGF/VEGFR inhibitors.

In addition, ovarian cancer treatment involves chemotherapy, surgery, hormone, radiation, and targeted therapies that aid in killing the cancer cells to provide relief from signs and systems. These therapeutics are conducted by medical practitioners across hospitals and specialty centers after determining several factors, such as the spread of the tumor, the general health of an individual, and the size and type of ovarian cancer. 

What are the major market drivers in the Ovarian Cancer Market ?

The escalating prevalence of epithelial, stromal, and germ cell cancer, especially among the female geriatric population, on account of the genetic mutation of BRCA2 or breast cancer gene 1 (BRCA1), is primarily driving the ovarian cancer market. Besides this, the elevating requirement for effective therapeutic drugs, including bevacizumab (Avastin) and pazopanib (Votrient), is further augmenting the market growth.

Moreover, the launch of several policies by the government bodies to sensitize consumers toward the treatments, symptoms, and benefits of early ovarian cancer diagnosis is also catalyzing the global market. Apart from this, the growing popularity of combination therapies in the healthcare sector to increase medicine efficacy and prevent drug resistance is acting as another significant growth-inducing factor.

Additionally, the ongoing patent expiration of branded medications has prompted pharmaceutical companies to launch novel recombinant drugs, which is also stimulating the market growth. Furthermore, the strategic collaborations among the leading players and the extensive research and development (R&D) activities to produce efficient therapeutic interventions are anticipated to propel the ovarian cancer market over the forecasted period. 

Click here to view detailed information with table of content: https://www.imarcgroup.com/ovarian-cancer-market

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Type:

o   Epithelial Ovarian Cancer

o   Germ Cell Ovarian Cancer

o   Stromal Cell Ovarian Cancer
 

Breakup by Treatment Type:

o   Immunotherapy

o   Chemotherapy

o   Targeted Therapy

o   Surgery

o   Others
 

Breakup by End User:

o   Hospitals

o   Homecare

o   Speciality Centre

o   Others

By Geography:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

List of Major Key Players:

The major players in the market are  

AbbVie Inc.

 Amneal Pharmaceuticals Inc.

 AstraZeneca plc, Eli Lilly and Company

 F. Hoffmann-La Roche AG, GSK plc

 Hikma Pharmaceuticals PLC

 Lupin Limited, Pfizer Inc.

and Teva Pharmaceutical Industries Ltd.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800